Successful Remission of Hemolytic-Uremic Syndrome During the Third-line Weekly Gemcitabine for Metastatic Breast Cancer

Sequential palliative chemotherapy for metastatic breast cancer incorporating weekly gemcitabine administered as three-weeks-on, one-week-off schedule is widely adopted throughout the East Asia region. Hemolytic-uremic syndrome (HUS) associated with weekly gemcitabine for a breast cancer patient is...

Descripción completa

Detalles Bibliográficos
Autores principales: Kok, Victor C, Wu, Sheng-Chung, Lee, Chien-Kuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972075/
https://www.ncbi.nlm.nih.gov/pubmed/24701120
http://dx.doi.org/10.4137/BCBCR.S14920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972075/
https://www.ncbi.nlm.nih.gov/pubmed/24701120
http://dx.doi.org/10.4137/BCBCR.S14920

Ejemplares similares